NL-OMON23637已完成不适用
A RANDOMIZED PHASE II STUDY INVESTIGATING THE ADDITION OF THE SPECIFIC COX-2 INHIBITOR CELECOXIB TO DOCETAXEL PLUS CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY FOR STAGE IC-IV EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CARCINOMASDoCa – Cel
Sanofi-AventisPfizer0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histologically confirmed epithelial ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer.
- •2.Age > 18 year
排除标准
- •1.ECOG performance status. > 2
- •2.Prior treatment with chemotherapy or radiotherapy.
研究者
相似试验
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas.Epithelial ovarian cancer, ovarian fallopian tube or primary peritoneal carcinomasNL-OMON25042VU medical center200
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200
已完成
不适用
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.Myelodysplastic syndrome (MDS)NL-OMON20915Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Postbus 2040; 3000 CA Rotterdam; Tel: +31 10 704 1560 Fax: +31 10 704 1028; e-mail: hdc@erasmusmc.nl200
终止
2 期
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NETSmall-cell Lung CancerNeuroendocrine CarcinomaNCT05420636Fox Chase Cancer Center20
招募中
不适用
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years.A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.Acute Myeloid Leukemia (AML), MyelodysplasiaNL-OMON19923HOVON Data Center185